UPB earnings analysis
What we found in UPB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Upstream Bio delivered $1.807 million of Q2 2026 revenue, approximately 92.8% above Q2 2025, but remains deeply loss-making with a $39.702 million quarterly net loss and $80.3 million six-month loss. Cash resources of $261.3 million are expected to fund operations through 2027, and clinical milestones remain on track, including 481 COPD enrollees and planned Phase 3 initiation in Q1 2027. The outlook is mixed because continued development depends on substantial funding, potential equity dilution and third-party manufacturing arrangements exposed to BIOSECURE-related restrictions.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue nearly doubled year over year
- Q2 2026 revenue was $1.807 million, up $0.870 million, or approximately 92.8%, from $0.937 million in Q2 2025. Revenue also increased from approximately $1.0 million in Q1 2026.
- Clinical investment continues
- The company reported a Q2 2026 net loss of $39.702 million. Six-month net loss was $80.3 million, compared with $67.2 million for the six months ended June 30, 2025.
- Cash runway maintained through 2027
- Cash, cash equivalents and short-term investments totaled $261.3 million at June 30, 2026, which management expects to fund planned operating expenses and capital expenditures through 2027.
- Clinical development milestones advanced
- The COPD clinical program completed enrollment at 481 participants, while Phase 3 trials for verekitug are targeted to begin in Q1 2027.
- ATM provides incremental financing flexibility
- Under the ATM program, the company had sold 239,797 shares for approximately $2.1 million of net proceeds as of June 30, 2026, after approximately $0.1 million of commissions.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Additional capital may dilute holders
- The company may issue up to $150.0 million of common stock under its ATM prospectus. As of June 30, 2026, it had sold 239,797 shares for approximately $2.1 million of net proceeds, creating potential future dilution and share-price pressure.
- BIOSECURE manufacturing exposure
- The company relies on third-party manufacturing, including WuXi Biologics, and could face costly supply transitions if a vendor is designated a biotechnology company of concern under the BIOSECURE Act. WuXi AppTec was identified on the Department of Defense's updated 1260H list on June 8, 2026, while BIOSECURE Act implementation remains incomplete.
- Geopolitical and funding-market volatility
- The newly updated geopolitical and market-volatility risk includes potential disruption from tariffs, trade restrictions, military conflicts and financial-market instability. The filing notes a 43-day U.S. government shutdown from October 1, 2025 through November 12, 2025, illustrating the potential for regulatory and capital-market disruption.
What they said about what is next.
Management expects cash, cash equivalents and short-term investments of $261.3 million to fund planned operating expenses and capital expenditure requirements through 2027, consistent with the prior outlook.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Upstream Bio reported a Q4 revenue of $668,000 for the period ended March 31, 2026, surpassing consensus estimates of $600,942. However, the company reported a larger-than-expected net loss of $40.6 million, translating…
- 10-K · March 26, 2026
- Upstream Bio (UPB) is a clinical-stage biotech focused on verekitug, a TSLP‑receptor monoclonal antibody which the company says is ~300‑fold more potent than tezepelumab and enables extended dosing intervals of up to 24…
- 10-Q · August 6, 2025
- Upstream Bio reported Q2 collaboration revenue of $937,000 and a net loss attributable to common stockholders of $39.97 million (loss per share $0.74). Revenue rose materially year-over-year while operating expenses and…
- 10-Q · May 6, 2025
- Upstream Bio reported collaboration revenue of $566,000 and a net loss of $27.27 million for Q1 2025, driven by a step-up in R&D spend to $25.8 million. Liquidity remains substantial with $71,312 in cash and $360,068 in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing UPB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever